Mylan and Lupin Receive European Marketing Authorization for Nepexto(R), Biosimilar Etanercept
HERTFORDSHIRE, England, PITTSBURGH and MUMBAI, India, June 4, 2020 -- (Healthcare Sales & Marketing Network) -- Mylan N.V. (NASDAQ: MYL) and Lupin Limited (Lupin) today announced that the European Commission (EC) has granted marketing authorization for Ne... Biopharmaceuticals, Generics, Regulatory Mylan, Lupin, Nepexto, biosimilar, Enbrel, etanercept, arthritis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 4, 2020 Category: Pharmaceuticals Source Type: news
Costs lowest when bDMARD sequences start with etanercept biosimilar
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - January 31, 2020 Category: Drugs & Pharmacology Source Type: news
Pharmacy benefits manager Abarca inks discount deal for Amgen's Enbrel
Abarca, a small Puerto Rico-based pharmacy benefits manager, said on Tuesday Amgen Inc had agreed to give its health insurer clients an additional discount on its blockbuster rheumatoid arthritis drug Enbrel, if patients discontinue taking it after three months. (Source: Reuters: Health)
Source: Reuters: Health - December 3, 2019 Category: Consumer Health News Tags: healthNews Source Type: news
iRhom2 inhibits bile duct obstruction-induced liver fibrosis
Chronic liver disease can induce prolonged activation of hepatic stellate cells, which may result in liver fibrosis. Inactive rhomboid protein 2 (iRhom2) is required for the maturation of A disintegrin and metalloprotease 17 (ADAM17, also called TACE), which is responsible for the cleavage of membrane-bound tumor necrosis factor–α (TNF-α) and its receptors (TNFRs). Here, using the murine bile duct ligation (BDL) model, we showed that the abundance of iRhom2 and activation of ADAM17 increased during liver fibrosis. Consistent with this, concentrations of ADAM17 substrates were increased in plasma samples f...
Source: Signal Transduction Knowledge Environment - October 28, 2019 Category: Science Authors: Sundaram, B., Behnke, K., Belancic, A., Al-Salihi, M. A., Thabet, Y., Polz, R., Pellegrino, R., Zhuang, Y., Shinde, P. V., Xu, H. C., Vasilevska, J., Longerich, T., Herebian, D., Mayatepek, E., Bock, H. H., May, P., Kordes, C., Aghaeepour, N., Mak, T. W., Tags: STKE Research Articles Source Type: news
Amgen Wins U.S. Patent Battle on Arthritis Drug Enbrel, Thwarting Novartis Amgen Wins U.S. Patent Battle on Arthritis Drug Enbrel, Thwarting Novartis
A U.S. judge on Friday said two patents relating to Amgen Inc ' s blockbuster rheumatoid arthritis drug Enbrel (etanercept) were valid, denying a challenge by Novartis AG, which is seeking to launch a copycat version.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - August 13, 2019 Category: Orthopaedics Tags: Rheumatology News Source Type: news
Amgen wins Enbrel patent protections — for now
Amgen has fought off a patent challenge from Novartis to its blockbuster anti-inflammatory, Enbrel. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - August 12, 2019 Category: Pharmaceuticals Source Type: news
Amgen wins U.S. patent battle on arthritis drug Enbrel, thwarting Novartis
A U.S. judge on Friday said two patents relating to Amgen Inc's blockbuster rheumatoid arthritis drug Enbrel were valid, denying a challenge by Novartis AG, which is seeking to launch a copycat version. (Source: Reuters: Health)
Source: Reuters: Health - August 9, 2019 Category: Consumer Health News Tags: healthNews Source Type: news
Etanercept Tx for Autoimmune Disease May Up Risk for IBD
MONDAY, July 15, 2019 -- Patients with autoimmune diseases have an increased risk for being diagnosed with Crohn disease (CD) or ulcerative colitis (UC) while under treatment with etanercept, according to a study published online July 2 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 15, 2019 Category: Pharmaceuticals Source Type: news
etanercept (Enbrel)
Title: etanercept (Enbrel)Category: MedicationsCreated: 3/2/1999 12:00:00 AMLast Editorial Review: 6/28/2019 12:00:00 AM (Source: MedicineNet Skin General)
Source: MedicineNet Skin General - June 28, 2019 Category: Dermatology Source Type: news
Infection Risk Lower With Certain Psoriasis Treatments
MONDAY, May 13, 2019 -- For patients with psoriasis treated with systemic medications, the risk for serious infection is reduced for new users of apremilast, etanercept, and ustekinumab versus methotrexate, according to a study published online May... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 13, 2019 Category: Pharmaceuticals Source Type: news
Eticovo (Etanercept Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 2, 2019 Category: Drugs & Pharmacology Source Type: news
Eticovo (Etanercept Injection) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 1, 2019 Category: Drugs & Pharmacology Source Type: news
FDA OKs Second Etanercept Biosimilar for Inflammatory Diseases FDA OKs Second Etanercept Biosimilar for Inflammatory Diseases
Etanercept-ykro (Eticovo) is approved across all eligible indications for rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, and polyarticular juvenile idiopathic arthritis.FDA Approvals (Source: Medscape Rheumatology Headlines)
Source: Medscape Rheumatology Headlines - April 30, 2019 Category: Rheumatology Tags: Rheumatology News Alert Source Type: news
FDA Approves Eticovo (etanercept-ykro), a Biosimilar to Enbrel (etanercept)
April 26, 2019 The FDA has approved Eticovo (etanercept-ykro), a biosimilar to U.S.-licensed Enbrel (etanercept).
A biosimilar product is a biological product that is approved based on a showing that it is highly similar to an already-FDA approved... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 27, 2019 Category: Drugs & Pharmacology Source Type: news
FDA Approves Eticovo (etanercept-ykro), a Biosimilar to Enbrel
INCHEON, Korea– As of April 2019– Samsung Bioepis Co., Ltd. today announced that the US Food and Drug Administration (FDA) has approved Eticovo (etanercept-ykro), a biosimilar referencing Enbrel (etanercept), across all eligible... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 27, 2019 Category: Drugs & Pharmacology Source Type: news
